Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a clinical study titled ‘MAGNETISMM-6’ to evaluate the efficacy and safety of Elranatamab in combination with other drugs for patients with newly diagnosed multiple myeloma who are not eligible for transplant. The study aims to determine if Elranatamab, combined with Daratumumab and Lenalidomide, or with Lenalidomide alone, provides better clinical outcomes compared to the existing combination of Daratumumab, Lenalidomide, and Dexamethasone.
The intervention involves testing Elranatamab, a bispecific antibody, which targets specific cells to induce a cytotoxic response. It is being tested in combination with Daratumumab, Lenalidomide, and Dexamethasone, which are established treatments for multiple myeloma.
This Phase 3 study is interventional, with a randomized, parallel assignment model and no masking, focusing on treatment efficacy. The study is divided into two parts, with the first part assessing safety and optimal dosing, and the second part evaluating disease progression and survival rates.
The study began on November 10, 2022, with its primary completion expected by July 28, 2025. These dates are crucial as they mark the progress and anticipated milestones of the study, impacting investor decisions.
Pfizer’s ongoing study could significantly influence its market position, especially if Elranatamab proves more effective, potentially boosting its stock value. Investors should watch for updates, as positive results could shift market dynamics, especially in comparison to competitors in the oncology sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.